African Pioneer Share Discussion Threads

[ltinvestor] 10/5/2005 08:17

The appointment of Chris Moore as non exec chairman , who took Torex from a £10m mkt cap to £350m in the same sector that Ascribe trades, is in my opinion of major significance.I would now expect a series of acquisitions and Ascribe to become a major consolidator in this sector.

[currypasty] 03/5/2005 07:51

29 April 2005

Ascribe profits with new contracts


Ascribe has cemented a good start to the year with three new contract wins and a number of licence extensions. The new business is expected to generate around £650,000 of sales income, with the added bonus of recurring maintenance revenue.

The health IT group has performed well since joining Aim last December. Broker Seymour Pierce expects profits of £1.1m, giving earnings of 0.9p this year, rising to £1.7m and 1.4p, respectively, in 2006.


Trading on 17 times 2006 earnings, the rating looks punchy. But, with earnings-enhancing acquisitions expected, Ascribe should further strengthen its position.

[v6syncro] 25/4/2005 13:16

It's a good job they have Protechnic that 'plugs a gap in Ascribe's exposure to the healthcare IT market' !!!!

[currypasty] 25/4/2005 12:17

RNS Number:4643L
Ascribe plc
25 April 2005




Press Release 25 April 2005



Ascribe plc


("Ascribe" or "the Group")


Trading Update




Ascribe (AIM:ASP), the health IT group focusing on medicines management,
announces further contract wins, licence extensions and a good start to 2005
trading. Ascribe believes it will continue to perform in line with analysts'
expectations in the second half of its financial year, ending on 30 June 2005.
The new business announced today will generate approximately #650k of sales
income with recurring maintenance revenue thereafter.



Ascribe's Pharmacy division has won three new contracts since the beginning of
2005. These contracts will run for between three and five years and include the
sale of Ascribe pharmacy software to the Co Durham & Darlington NHS Trust and
the Royal Wolverhampton Hospitals NHS Trust. Furthermore, in the same period the
Pharmacy Systems at Darlington Memorial, Bishop Auckland General and Kettering
General Hospitals have been installed and gone live.



In the Group's Mental Health and Child Care division the widening community use
of ePEX software in the installed base has resulted in extensions to customer
user licences. Since January the Primary Care Trusts in Merseyside, Barnet,
Solihull, Devon, Rotherham, West Kent, North Warwickshire and Plymouth have all
extended their licences to embrace extended electronic care management across
health and social care communities.



The upgraded ePEX product, a shared information system for health and social
care, will incorporate an optional major new messaging component which will
enable users to interface with other systems used in local government
departments and the new Child Trusts, thereby extending its coverage. This
software is expected to be used later in the year for connection to the National
NHS Data Spine (the new national network and repository for Patient Record
Management).



Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: "I am very
pleased with the Group's performance in 2005. The new contract wins and licence
extensions underline the market's favourable impression of Ascribe's software
solutions that meets the real needs of our customers today. The Group's growth
in market share and profitability is delivering the shareholder value envisaged
at the time of flotation.

[currypasty] 08/4/2005 09:36

somone has just dumped 100k, so cheap shares on offer if anyone interested !

[currypasty] 24/3/2005 12:46

IC mag today... hence the drop ????


Ascribe floated on the Alternative Investment Market (Aim) last December at 18p a share, raising a net £4.3m in the process. That funded its acquisition of Protechnic, which will cost up to £5.8m. Protechnic, which makes profits of around £500,000 a year, plugs a gap in Ascribe's exposure to the healthcare IT market.

Ascribe's traditional sector has been the secondary healthcare market, providing software for hospitals and pharmacies so that they can manage their prescription services. Protechnic's field is primary healthcare, GP's surgeries, mental health and childcare, which should provide a good platform to tap into the opportunities arising from further consolidation within the medicines-management sector.

The results show Ascribe moving into the black, with the prospect of a strong second half, driven by organic growth in Ascribe's original business and a contribution from Protechnic. So Seymour Pierce expects full-year pre-tax profits (before goodwill amortisation) of £1.1m, giving EPS of 0.9p.


These are early days for Ascribe, which is on the lookout for further acquisitions. Trading on a forward PE ratio of 32, the share rating looks full enough. Fairly priced.

[currypasty] 16/3/2005 07:42

Press Release 16 March 2005

Ascribe Plc

("Ascribe" or "the Group")

Interim Results for the six months ended 31 December 2004


Ascribe (AIM:ASP), the health IT group focusing on medicines management, reports
its maiden Interim Results for the six months ended 31 December 2004.


Highlights

- acquisition of Protechnic Exeter Limited
- successful debut on AIM
- turnover of #1.64 million (*Pro forma 6 months: #3.05 million)
- EBITDA of #112k (*Pro forma 6 months: #428k)
- profit before interest and tax of #23k (*Pro forma 6 months: #312k)
- basic loss per share of 0.1 pence (*Pro forma 6 months: adjusted basic earnings per share 0.28 pence)


*Pro forma information shows the results for the Group as if it had been trading
in its current form for the full 6 month period.


Commenting on the Interim Results, Stephen Critchlow, Chairman and Chief
Executive of Ascribe plc, said: "I am extremely pleased with the progress of
the Group since flotation. The Protechnic acquisition is integrating well into
the Ascribe business. Ascribe's strategy of building its position in the
medicines management market through organic growth and through a number of
acquisitions of profitable companies, offering complementary established systems
to customers needing a medicines management solution, is taking shape.



"The business has a good order book, a strong sales pipeline reinforced by an
excellent record of winning public tenders, a healthy record of providing
follow-on products to existing customers and a recurring maintenance contract
income level running at 59% of sales in the period. I remain confident about
the Group's prospects for 2005 and beyond."





For further information:
Ascribe plc
Stephen Critchlow, Chairman and Chief Executive Tel: [phone]
[e-mail]
Jeremy Lee, Group Finance Director
[e-mail] www.ascribe.com

[roofer2] 15/3/2005 18:56

Hi All
Hope for good results tomorrow, and
good news on any NHS contract wins.
strange bid price today.
looking v/good

[thoa] 28/2/2005 14:08

Oops forgot the link

or go via www.ascribe.com

tommie

[thoa] 28/2/2005 14:06

Hi,

Not new news but announcement only appeared on ascribe site today - very postive article especially that the software has been implemented as part of the National Programme for Information technology. As far as I understand all NHS trusts have to implement this programme over the next few years. Plenty of business to go for.

Cheers tommie

[currypasty] 28/2/2005 09:01

punters must think results will be good, plenty of buys today, and up 2.5p

[currypasty] 28/2/2005 08:23

RNS Number:0757J
Ascribe plc
28 February 2005


Press Release 28 February 2005

Ascribe Plc

("Ascribe" or "the Company")

Notice of Interim Results - Wednesday 16 March 2005

Ascribe (AIM:ASP), the health IT group focusing on medicines management, will
announce its maiden Interim Results for the period ended 31 December 2004 on
Wednesday 16 March 2005.

[currypasty] 01/2/2005 08:33

Another decent rise this morning.,..

up 6.6% at 31.0 - 34.0

[v6syncro] 31/1/2005 17:02

"our loyal user base!" - So why have Great Ormond Street Hospital replaced them!?

[currypasty] 31/1/2005 16:11

31 January 2005


Press Release 31 January 2005

Ascribe plc

("Ascribe" or "the Group")

Trading Update


Ascribe (AIM:ASP), the health IT group focusing on medicines management,
announces that since its AIM flotation on 17 December 2004 and the recent
acquisition of Protechnic-Exeter, trading is in line with management
expectations.


With recurring maintenance contract revenues in excess of 60 per cent of
historical sales, a healthy order book and a high level of tendering activity -
both in the UK and overseas - Ascribe believes it will continue to perform in
line with expectations in the second half of the financial year, ending on 30
June 2005.


Ascribe's Pharmacy Division has won four new contracts since flotation, with a
combined capital and first year maintenance income value in excess of #375,000.
These contracts will run for between three and five years and will include the
sale of Ascribe pharmacy software to Kettering General Hospitals NHS Trust and
Huddersfield and Calderdale NHS Trust, together with ward-based medicines
management software to a Scottish-based customer.


In addition, Ascribe's Community Care division (including Mental Health
Services) is upgrading its ePEX product, a shared information system for health
and social care, currently deployed in 35 local health communities across Great
Britain and Ireland. A major new messaging component has been added to the
software which will enable users to interface with other systems used in local
government departments and the new Child Trusts, thereby extending its coverage.
This software is expected to be used later in the year for connection to the
National NHS Data Spine (the new national network and repository for Patient
Record Management).

The Ascribe software has been implemented in several new clinical areas over the
last year, to include single assessment, electronic care management across
health and social care, and substance misuse services. This has resulted in far
greater use of the system by health care professionals in the community, and in
turn, has brought in significant new revenue through increased sales of end user
licenses.

Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: "The
performance of the Group after the acquisition of Protechnic-Exeter is meeting
all our expectations. The new combined team is working on a group sales and
product strategy that will contribute to our long-term growth.


"This success comes from delivering medicines management software that meets the
real needs of our customers today. We believe the firm order book, our loyal
user base, and a clear sales and product strategy will deliver sustainable
growth."


The interim results for the period to 31 December 2004 are expected to be
announced on Wednesday 16 March 2005.

[roofer2] 31/1/2005 10:24

Hi, yes got these in Dec as i said, just phoned T.D.Waterhouse for share certificate as i still have not got it, there are no problems except not enough shares on the market, this is looking good and still no sells

[malgowland] 31/1/2005 10:12

Hi Roofer2,

big jump today...you in this stock yet?

MG (T Mc)

[v6syncro] 31/1/2005 09:39

On very low volume! Maybe just sucking you in!?

[currypasty] 31/1/2005 09:29

Very impressive rise this morning !

up 21%

[roofer2] 29/1/2005 20:50

There has been some big buys in the last month, not many small trades, it could be institution buys, seeing there are no sells, things are going to get interesting D.O.R.

[roofer2] 16/1/2005 17:08

Hello all, at last i have found the thread for ascribe, been on 2 others for the last month ASP-ABE, hope to see some good acquisitions, with good backing and money to spend, then interest will take of.................. sorry should have been... ABE-APS , that many could be reason for lack of interest

[ltinvestor] 12/1/2005 10:10

Further institutional interest I suspect.Having bought £2.5m worth of shares I cannot imagine Chris Moore (founder of Torex) taking a back seat and I would not be surprised if he were to take a very active part in the running and expansion of this business.

[currypasty] 12/1/2005 09:02

2 very large trades ..delayed.. yesterday

up 1.5 again today, so perhaps more of the same

no punter interest in this yet, shame, could do very well

[currypasty] 11/1/2005 13:03

Up 1.5... no trades showing !!